Logo

GLTO

Galecto, Inc.

GLTO

Galecto, Inc. • NASDAQ
$17.78 ▲ 2.24% (+0.39)
Market Cap $23.60 M
52w High $33.60
52w Low $2.01
Dividend Yield 0%
P/E -1.47
Volume 39.25K
Outstanding Shares 1.33M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.156M ▼ $-3.133M ▲ 0% $-2.36 ▲ $-3.123M ▲
Q2-2025 $0 $3.421M ▲ $-3.437M ▼ 0% $-2.6 ▼ $-3.412M ▼
Q1-2025 $0 $2.599M ▼ $-2.533M ▲ 0% $-1.92 ▲ $-2.591M ▲
Q4-2024 $0 $2.702M ▼ $-6.741M ▼ 0% $-5.83 ▼ $-6.744M ▼
Q3-2024 $0 $3.84M $-3.883M 0% $-3.39 $-3.78M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.606M ▼ $10.736M ▼ $4.07M ▲ $6.666M ▼
Q2-2025 $10.211M ▼ $13.691M ▼ $2.738M ▲ $10.953M ▼
Q1-2025 $11.939M ▼ $15.365M ▼ $1.656M ▲ $13.709M ▼
Q4-2024 $14.175M ▼ $17.132M ▼ $1.301M ▼ $15.831M ▼
Q3-2024 $19.678M $23.376M $2.441M $20.935M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.133M ▲ $-2.616M ▼ $0 $0 $-2.605M ▼ $-2.616M ▼
Q2-2025 $-3.437M ▼ $-2.237M ▲ $0 $0 $-1.728M ▲ $-2.237M ▲
Q1-2025 $-2.533M ▲ $-2.439M ▲ $0 $0 $-2.236M ▲ $-2.439M ▲
Q4-2024 $-6.741M ▼ $-4.936M ▼ $0 $0 $-5.503M ▼ $-4.936M ▼
Q3-2024 $-3.883M $-3.651M $0 $0 $-3.184M $-3.651M

Five-Year Company Overview

Income Statement

Income Statement Galecto is a classic early‑stage biotech: it has no product revenue yet and has reported operating and net losses every year. The losses appear to be relatively steady and driven mainly by research and development and overhead, not by any one‑off event. Earnings per share look very negative, but that is heavily influenced by the reverse stock split and share count changes, not by a dramatic swing in the underlying business. Overall, the income statement shows a company still firmly in the investment phase, with no commercial engine in place yet.

Balance Sheet

Balance Sheet The balance sheet is small, simple, and dominated by cash, with very little in the way of physical assets or long‑term investments. Importantly, the company carries no financial debt, so it is not burdened by interest payments or looming loan maturities. Equity largely reflects the cash raised from investors over time. Total assets have trended downward as losses consume cash, although the recent capital raise mentioned in the narrative suggests the current reported balance sheet may understate today’s liquidity position. Financial strength therefore rests almost entirely on available cash and the company’s ability to access capital markets.

Cash Flow

Cash Flow Cash flow patterns match what you would expect from a clinical‑stage biotech. The company consistently uses cash in its operations, reflecting spending on trials, research, and corporate costs, with no offsetting product cash inflows. Capital expenditure is negligible, so free cash flow is effectively the same as operating cash flow and is consistently negative. The absolute level of cash burn looks modest compared with larger biotech peers, but it is still meaningful relative to the small asset base, keeping ongoing funding and cost control as central issues.

Competitive Edge

Competitive Edge Galecto competes in highly specialized corners of oncology and hematology, targeting specific genetic and molecular drivers of disease. Its edge comes from deep expertise in galectin biology, newly added know‑how in mutant calreticulin, and a differentiated dual‑target approach in acute myeloid leukemia. Strong patent protection and a focus on narrow, underserved indications help create a niche where few direct competitors operate today. However, the company is up against larger, well‑funded players in AML and myeloproliferative neoplasms, and all of its key assets are still preclinical or early clinical. Until human data clearly show superior safety or efficacy, its competitive position remains promising but unproven.

Innovation and R&D

Innovation and R&D R&D is the heart of the company. Galecto has deliberately pivoted from fibrosis to precision oncology, reshaping its pipeline around three pillars: a targeted antibody against mutant calreticulin for certain blood cancers, a first‑in‑class dual ENL‑YEATS and FLT3 inhibitor for leukemia, and a galectin‑3 inhibitor intended to boost the effectiveness of cancer immunotherapies. This is an ambitious strategy that leverages its historic galectin expertise while adding new platforms through acquisition. The programs are innovative and mechanistically interesting, but they are mostly at the preclinical or early‑human stage, so scientific, clinical, and regulatory risks are very high and timelines to proof‑of‑concept stretch several years into the future.

Summary

Galecto is a small, clinical‑stage biotech with no commercial revenue, ongoing operating losses, and a cash‑heavy, debt‑free balance sheet. Its financial story today is about controlled cash burn and continued access to funding rather than profitability. Strategically, the company has made a bold shift into precision oncology, focusing on highly specific targets in rare blood cancers and immuno‑oncology combinations. This creates a focused, differentiated pipeline with meaningful upside if the science translates well in humans, but it also concentrates risk in a handful of early‑stage programs. Overall, Galecto represents a typical high‑uncertainty biotech profile: financially dependent on external capital and scientifically dependent on future trial results to validate its new direction.

NEWS

November 10, 2025 · 7:00 AM UTC

Galecto Announces Acquisition of Damora Therapeutics

Read more

November 6, 2025 · 4:30 PM UTC

Galecto Reports Third Quarter 2025 Operating and Financial Results

Read more